Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified
Menée sur 25 patientes d'âge supérieur à 65 ans et atteintes d'un cancer avancé du sein, cette étude évalue l'efficacité et la toxicité de la doxorubicine liposomale pégylée, en traitement de première ligne, et identifie des marqueurs prédictifs de la réponse thérapeutique
We investigated the efficacy and safety of single-agent pegylated liposomal doxorubicin (PLD) as first-line treatment for elderly women with advanced breast cancer and evaluated predictive markers for response and toxicity. 25 women [greater-or-equal, slanted]65 years received 40 mg/m2 PLD every 28 days. Time to treatment failure (TTF), response rate, time to progression (TTP), overall survival (OS), and analysis of the ABCB1 single nucleotide polymorphism (SNP), the MRN complex, and TOPOII[alpha] were analyzed. A mean of 7.4 cycles PLD were administered and TTF was 5.5 months and OS 20.6 months. ABCB1 SNPs were found to correlate to both efficacy and toxicity, while tumor expression of the MRN complex and TOPOII[alpha] correlated to TTP. PLD is a safe and effective treatment for elderly breast cancer patients. Also potential predictive markers were identified.
http://www.sciencedirect.com/science/article/pii/S0304383511004319